Evidence map›Paper›PMID 39351195›Full record

ArticleiScience2024

SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activity.

Elizabeth J Martinez, William C Chang, Wei-Hung Chen, Agnes Hajduczki, Paul V Thomas, Jaime L Jensen, Misook Choe, Rajeshwer S Sankhala, Caroline E Peterson, Phyllis A Rees and 26 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Elizabeth J MartinezEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
William C ChangEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Wei-Hung ChenEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Agnes HajduczkiEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Paul V ThomasEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Jaime L JensenEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Misook ChoeEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Rajeshwer S SankhalaEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Caroline E PetersonEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Phyllis A ReesEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Jordan KimnerHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Sandrine SomanViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Caitlin KuklisViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Letzibeth Mendez-RiveraHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Vincent DussuptHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
Jocelyn KingEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Courtney CorbettEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Sandra V MayerEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Aldon FernandesBharat Serums and Vaccines Ltd., Mumbai, Maharashtra, India.
Kripa MurzelloTrudeau Institute, Saranac Lake, NY, USA.
Tres CookenhamTrudeau Institute, Saranac Lake, NY, USA.
Janine HvizdosTrudeau Institute, Saranac Lake, NY, USA.
Larry KummerTrudeau Institute, Saranac Lake, NY, USA.
Tricia HartTrudeau Institute, Saranac Lake, NY, USA.
Kathleen LanzerTrudeau Institute, Saranac Lake, NY, USA.
Julian GambacurtaTrudeau Institute, Saranac Lake, NY, USA.
Matthew ReaganTrudeau Institute, Saranac Lake, NY, USA.
Debbie DusoTrudeau Institute, Saranac Lake, NY, USA.
Sandhya VasanEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Natalie D CollinsEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Nelson L MichaelCenter for Infectious Diseases Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Shelly J KrebsU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Gregory D GromowskiViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Kayvon ModjarradEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
John KaundinyaBSV Biosciences, Inc., Morgan Hill, CA, USA.
M Gordon JoyceEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rapid emergence of SARS-CoV-2 variants of concern (VoC) and the threat of future zoonotic sarbecovirus spillover emphasizes the need for broadly protective next-generation vaccines and therapeutics. We utilized SARS-CoV-2 spike ferritin nanoparticle (SpFN), and SARS-CoV-2 receptor binding domain ferritin nanoparticle (RFN) immunogens, in an equine model to elicit hyperimmune sera and evaluated its sarbecovirus neutralization and protection capacity. Immunized animals rapidly elicited sera with the potent neutralization of SARS-CoV-2 VoC, and SARS-CoV-1 pseudoviruses, and potent binding against receptor binding domains from sarbecovirus clades 1b, 1a, 2, 3, and 4. Purified equine polyclonal IgG provided protection against Omicron XBB.1.5 virus in the K18-hACE2 transgenic mouse model. These results suggest that SARS-CoV-2-based nanoparticle vaccines can rapidly produce a broad and protective sarbecovirus response in the equine model and that equine serum has therapeutic potential against emerging SARS-CoV-2 VoC and diverse sarbecoviruses, presenting a possible alternative or supplement to monoclonal antibody immunotherapies.

Indexed as

ImmunologyVirology

Identifiers

PMID39351195
PMCPMC11440237

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.